Oppenheimer Asset Management Inc. Purchases 1,713 Shares of Heska Corporation (HSKA)
Oppenheimer Asset Management Inc. boosted its position in Heska Corporation (NASDAQ:HSKA) by 63.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,412 shares of the medical research company’s stock after acquiring an additional 1,713 shares during the period. Oppenheimer Asset Management Inc. owned 0.06% of Heska Corporation worth $450,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the stock. Swiss National Bank bought a new position in Heska Corporation in the second quarter valued at about $1,082,000. Principal Financial Group Inc. boosted its holdings in Heska Corporation by 3.0% in the second quarter. Principal Financial Group Inc. now owns 51,337 shares of the medical research company’s stock valued at $5,240,000 after acquiring an additional 1,477 shares during the last quarter. Neuberger Berman Group LLC boosted its holdings in Heska Corporation by 1.0% in the second quarter. Neuberger Berman Group LLC now owns 449,574 shares of the medical research company’s stock valued at $45,888,000 after acquiring an additional 4,329 shares during the last quarter. Geneva Advisors LLC boosted its holdings in Heska Corporation by 565.4% in the second quarter. Geneva Advisors LLC now owns 75,499 shares of the medical research company’s stock valued at $7,706,000 after acquiring an additional 64,153 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its holdings in Heska Corporation by 17.5% in the second quarter. Victory Capital Management Inc. now owns 1,133 shares of the medical research company’s stock valued at $116,000 after acquiring an additional 169 shares during the last quarter. Institutional investors and hedge funds own 81.44% of the company’s stock.
Heska Corporation (NASDAQ:HSKA) opened at 93.62 on Friday. The firm’s 50-day moving average price is $99.06 and its 200-day moving average price is $98.70. Heska Corporation has a one year low of $46.51 and a one year high of $115.00. The company has a market cap of $676.50 million, a PE ratio of 47.72 and a beta of 0.91.
Heska Corporation (NASDAQ:HSKA) last released its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. Heska Corporation had a return on equity of 15.87% and a net margin of 10.70%. The firm had revenue of $34.30 million for the quarter, compared to analyst estimates of $33.35 million. During the same quarter in the previous year, the company posted $0.35 EPS. The business’s revenue was up 14.3% on a year-over-year basis. On average, equities research analysts forecast that Heska Corporation will post $2.04 earnings per share for the current fiscal year.
Several equities analysts recently issued reports on HSKA shares. Aegis started coverage on Heska Corporation in a report on Thursday, June 1st. They issued a “buy” rating and a $114.50 price target on the stock. Benchmark Co. raised their target price on Heska Corporation from $106.00 to $120.00 and gave the stock a “buy” rating in a report on Thursday, August 3rd. BidaskClub upgraded Heska Corporation from a “hold” rating to a “buy” rating in a report on Thursday, August 3rd. Zacks Investment Research upgraded Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 target price on the stock in a report on Friday, August 4th. Finally, B. Riley restated a “neutral” rating and set a $96.50 target price on shares of Heska Corporation in a report on Thursday, August 3rd. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $105.20.
In other Heska Corporation news, EVP Nancy Wisnewski sold 825 shares of the company’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $102.21, for a total value of $84,323.25. Following the sale, the executive vice president now owns 38,114 shares in the company, valued at approximately $3,895,631.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO John Mcmahon sold 2,608 shares of the company’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $101.17, for a total value of $263,851.36. Following the completion of the sale, the chief financial officer now owns 193 shares in the company, valued at approximately $19,525.81. The disclosure for this sale can be found here. Insiders own 14.70% of the company’s stock.
Heska Corporation Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Stock Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related stocks with our FREE daily email newsletter.